07.12.23
Supplementing with an oral CBD formulation by NextEvo Naturals led to the activation of immune factors in a safety, tolerability, pharmacokinetics, and pharmacodynamic study involving 26 participants, according to the company.
Over a three-day period, the formula was tested at two concentrations consumed at twice-daily intervals, which led to steady-state blood levels, at which point the formula demonstrated strong tolerability and safety profiles with no adverse events reported even at the higher concentration.
CBD consumption resulted in significant modulation of LPS-stimulated whole blood cytokines assays (TruCulture, RBM), highlighting potential immuno-modulatory effects. Serum cytokines also exhibited concentration-dependent immunomodulatory effects, which the authors suggested was a leading indicator for a product’s ability to regulate the body’s inflammatory response.
"This study represents a crucial step forward in our understanding of CBD's potential impact on
the immune response,” said John McDonagh, CEO of NextEvo Naturals. “The safety and
pharmacokinetic profile support the twice-daily administration of our novel, water-soluble CBD
oral formulation while the divergent immune effects observed between concentrations tested
underscore the need for additional research to optimize CBD preparations and consumption
levels for immune effects."
The company plans to publish the results of the study in the coming months.
Over a three-day period, the formula was tested at two concentrations consumed at twice-daily intervals, which led to steady-state blood levels, at which point the formula demonstrated strong tolerability and safety profiles with no adverse events reported even at the higher concentration.
CBD consumption resulted in significant modulation of LPS-stimulated whole blood cytokines assays (TruCulture, RBM), highlighting potential immuno-modulatory effects. Serum cytokines also exhibited concentration-dependent immunomodulatory effects, which the authors suggested was a leading indicator for a product’s ability to regulate the body’s inflammatory response.
"This study represents a crucial step forward in our understanding of CBD's potential impact on
the immune response,” said John McDonagh, CEO of NextEvo Naturals. “The safety and
pharmacokinetic profile support the twice-daily administration of our novel, water-soluble CBD
oral formulation while the divergent immune effects observed between concentrations tested
underscore the need for additional research to optimize CBD preparations and consumption
levels for immune effects."
The company plans to publish the results of the study in the coming months.